Our Data-Driven Workflow Drives Our Discovery Efforts
We believe RayzeBio is leading innovation in targeted radiopharmaceutical therapies. Our discovery engine and approach have allowed us to systematically evaluate over 20 targets involving over 500 in vivo experiments since our inception in 2020. Our state of the art 28,000 sq ft radiopharmaceutical research facility, based in San Diego, enables us to carry out all key aspects for discovery of novel drug candidates.
This center of excellence includes
- Radiochemistry labeling lab for alpha and beta radioisotopes
- Vivarium with molecular imaging and biodistribution analysis
- Full in-vitro biological characterization
- Small molecule and peptide chemistry capabilities
- DMPK suite
We prosecute diverse sets of binders against clinically validated cancer targets through an iterative process involving in-vitro screening, X-ray crystallography, linker and radiolabeling optimization, and in-vivo screening with molecular imaging and biodistribution analysis.
We have completed over 500 in vivo studies, which has provided us with broad proprietary and critical insights on identifying what we regards as key attributes essential in discovering novel RPT drug candidates.